Mytatrienediol
| Code | Size | Price |
|---|
| TAR-T33545-5mg | 5mg | £850.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Mytatrienediol is a synthetic, steroidal, weak estrogen and estrogen ether derived from estriol.
CAS:
5108-94-1
Formula:
C20H28O3
Molecular Weight:
316.441
Purity:
0.98
SMILES:
[H][C@@]12C[C@](C)(O)[C@H](O)[C@@]1(C)CC[C@]1([H])c3ccc(OC)cc3CC[C@@]21[H]
References
SPENCER H, KABAKOW B, SAMACHSON J, LASZLO D. Metabolic effects of mytatrienediol in man. J Clin Endocrinol Metab. 1959 Dec;19:1581-96. PubMed PMID: 13833251.
COOK DL, CALHOUN DW, EDGREN RA. Lipodiatic and antiatherogenic properties of mytatrienediol and various estrogenic substances. Arch Int Pharmacodyn Ther. 1962 Jan 1;135:91-104. PubMed PMID: 13881041.
KABAKOW B, SPENCER H. Effects of mytatrienediol in multiple myeloma, metastatic bone disease, and osteoporosis. Arch Intern Med. 1960 Jun;105:905-13. PubMed PMID: 14408289.